Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(7):507; doi:10.1093/jnci/96.7.507
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

In Brief

The first 10% of the full text of this article appears below.

Aromatase Inhibitor After Tamoxifen Improves Disease-Free Survival

Postmenopausal breast cancer patients who took the aromatase inhibitor exemestane after 2 to 3 years of tamoxifen had a reduced chance of recurrence and increased disease-free survival compared with patients who remained on tamoxifen, according to results from the Intergroup Exemestane Study.

Taking tamoxifen after treatment for breast cancer reduces a . . . [Full Text of this Article]

Investigators Characterize Colorectal Cancer Among WHI Participants


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?